The test, called HPV-DeepSeek, detects microscopic fragments of HPV DNA that have broken off from a tumor and entered the ...

The FDA has granted fast track designation to the investigational drug CRB-701 for recurrent or metastatic head and neck ...

The FDA has granted fast track designation to the antibody-drug conjugate (ADC) CRB-701 for the treatment of recurrent or ...

While some patients may view head and neck cancer screenings as an unnecessary optional screening, these exams can be ...

This guide for newly diagnosed patients provides key information to help you understand your options and have informed ...

First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients ...

A new analysis finds that nearly half of head and neck cancer trials go unpublished, particularly those that lack ...

This is where Robot assisted surgery has transformed the landscape of head and neck cancer treatment. Unlike conventional open surgery, which may requ ...

Human papillomavirus (HPV) causes around 70% of head and neck cancers in the United States, making it the most common cancer ...

Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted ...

Completing treatment for head and neck cancer is a milestone, but recovery is an ongoing journey. With follow-ups, ...